Serum Homocysteine and Folate Levels in Korean Schizophrenic Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective This study was conducted to confirm the results of the authors’ previous research on schizophrenia manifesting high serum homocysteine and low folate levels. This study is anchored on a theory that a high serum homocysteine concentration affects schizophrenia by virtue of a neurotoxic mechanism, and on a report that some schizophrenia patients with high homocysteine levels benefited from high folate ingestion. Methods The serum homocysteine, folate, and vitamin B12 levels of 236 normal-control-group subjects and 234 schizophrenia subjects who met the diagnostic criteria based on DSM-IV-TR were compared. The homocysteine levels were measured via fluorescence polarization immunoassay, and the folate and vitamin B12 levels were determined via radioimmunoassay. Results The homocysteine levels of the patient group were significantly higher than those of the normal control group. The homocysteine level was more negatively correlated with the folate level in the schizophrenia group than in the control group. The percentages of female and male schizophrenia subjects manifesting high homocysteine levels were 33.8 and 51.5%, respectively. The percentage of schizophrenia subjects with low folate levels was 66.2%. In the low- and normal-folate-level groups, the patient group showed significantly higher homocysteine levels than the normal control group. The low-folate-level patient group particularly showed significantly higher homocysteine levels than the low-folate-level normal control group. Conclusion Some schizophrenia patients with high serum homocysteine levels may have the genetic defect of having low folate serum levels. In such cases, folate ingestion may be a good management modality for clinical improvement.
Abstract
Objective This study was conducted to confirm the results of the authors’ previous research on schizophrenia manifesting high serum homocysteine and low folate levels. This study is anchored on a theory that a high serum homocysteine concentration affects schizophrenia by virtue of a neurotoxic mechanism, and on a report that some schizophrenia patients with high homocysteine levels benefited from high folate ingestion. Methods The serum homocysteine, folate, and vitamin B12 levels of 236 normal-control-group subjects and 234 schizophrenia subjects who met the diagnostic criteria based on DSM-IV-TR were compared. The homocysteine levels were measured via fluorescence polarization immunoassay, and the folate and vitamin B12 levels were determined via radioimmunoassay. Results The homocysteine levels of the patient group were significantly higher than those of the normal control group. The homocysteine level was more negatively correlated with the folate level in the schizophrenia group than in the control group. The percentages of female and male schizophrenia subjects manifesting high homocysteine levels were 33.8 and 51.5%, respectively. The percentage of schizophrenia subjects with low folate levels was 66.2%. In the low- and normal-folate-level groups, the patient group showed significantly higher homocysteine levels than the normal control group. The low-folate-level patient group particularly showed significantly higher homocysteine levels than the low-folate-level normal control group. Conclusion Some schizophrenia patients with high serum homocysteine levels may have the genetic defect of having low folate serum levels. In such cases, folate ingestion may be a good management modality for clinical improvement.
참고문헌 (29)
- Petronijević ND, "Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.1921~1926 (2008)
- Kale A, "Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: Implications for altered one-carbon metabolism", Psychiatry Res, 175, pp.47~53 (2010)
- Furie KL, "Homocyst(e)ine and stroke", Semin Neurol, 26, pp.24~32 (2006)
- Seshadri S, "Plasma homocysteine as a risk factor for dementia and Alzh-eimer’s disease", N Engl J Med, 346, pp.476~483 (2002)
- 김재민, "Folate, Vitamin B12, and Homocysteine as Risk Factors for Cognitive Decline in the Elderly", PSYCHIATRY INVESTIGATION, 5(1), pp.36~40 (2008), 대한신경정신의학회
- O’Suilleabhain PE, "Clinical course in Parkinson’s disease with elevated homocysteine", Parkinsonism Relat Disord, 12, pp.103~107 (2006)
- Levine J, "Elevated homocysteine levels in young male patients with schizophrenia", Am J Psychiatry, 159, pp.1790~1792 (2002)
- Durand P, "Impaired homocysteine metabolism and atherothrombotic disease", Lab Invest, 81, pp.645~672 (2001)
- Kruman II, "Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity", J Neurosci, 20, pp.6920~6926 (2000)
- 김원기, "Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 94, pp.5923~5928, NATL ACAD SCIENCES
- Levine J, "Homocysteine-reducing strategies improve symptoms in chronic schi-zophrenic patients with hyperhomocysteinemia", Biol Psychiatry, 60, pp.265~269 (2006)
- Freeman JM, "Folate-responsive homocystinuria and “schizophrenia”. A defect in methylation due to deficient 5, 10-methylenetetrahydrofolate reductase activity", N Engl J Med, 292, pp.491~496 (1975)
- Regland B, "Homocysteinemia and schizophrenia as a case of methylation dificiency", J Neural Transm Gen Sect, 98, pp.143~152 (1994)
- Jacques PF, "Relation between folate status, a common mutation in me-thylenetetrahydrofolate reductase, and plasma homocysteine concentrations", Circulation, 93, pp.7~9 (1996)
- Joober R, "Association between the methylenetetrahydrofolate reductase 677C → T missense mutation and schizophrenia", Mol Psychiatry, 5, pp.323~326 (2000)
- García-Miss Mdel R, "Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia", J Psychiatr Res, 44, pp.441~446 (2010)
- American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders" (1994), American Psychiatric Press
- Nygård O, "Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study", Am J Clin Nutr, 67, pp.263~270 (1998)
- Susser E, "Schizoph-renia and impaired homocysteine metabolism: a possible association", Biol Psychiatry, 44, pp.141~143 (1998)
- Virgos C, "Plasma homocysteine and the methylenetetrahydrofolate reductase C677T gene variant: lack of association with schizophrenia", Neuroreport, 10, pp.2035~2038 (1999)
- 김원기, "Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 94, pp.5923~5928, NATL ACAD SCIENCES
- Spiro HR, "Schizophrenia in a patient with a defect in methionine metabolism", J Nerv Ment Dis, 141, pp.285~290 (1965)
- Cohen SM, "The administration of methionine to schizophrenic patients: a review of ten studies", Biol Psychiatry, 8, pp.209~225 (1974)
- Brune GG, "Effects of methionine loading on behavior of schizophrenic patients", J Nerv Ment Dis, 134, pp.447~450 (1962)
- Regland B, "Homocysteinemia is a common feature of schizophrenia", J Neural Tr-ansm Gen Sect, 100, pp.165~169 (1995)
- Pasquier F, "Metylenetetrahydrofolate reductase deficiency revealed by a neuropathy in a psychotic adult", Neurol Neurosurg Psychiatry, 57, pp.765~766 (1994)
- Mudd SH, "N-5,10-methylenetetrahydrofolate reductase deficiency and schizophrenia: a working hypothesis", J Psychiatr Res, 11, pp.259~262 (1974)
- Regland B, "Homozygous thermolabile metylenetetrahydrofolate reductase in schi-zophrenia-like psychosis", J Neural Transm, 104, pp.931~941 (1997)
- Susser E, "Schizophrenia and impaired homocysteine metabolism: a possible association", Biol Psychiatry, 44, pp.141~143 (1998)